151 related articles for article (PubMed ID: 15298179)
1. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity.
Pakkala M; Jylhäsalmi A; Wu P; Leinonen J; Stenman UH; Santa H; Vepsäläinen J; Peräkylä M; Närvänen A
J Pept Sci; 2004 Jul; 10(7):439-47. PubMed ID: 15298179
[TBL] [Abstract][Full Text] [Related]
2. A structural model for the prostate disease marker, human prostate-specific antigen.
Villoutreix BO; Getzoff ED; Griffin JH
Protein Sci; 1994 Nov; 3(11):2033-44. PubMed ID: 7535613
[TBL] [Abstract][Full Text] [Related]
3. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
4. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
[TBL] [Abstract][Full Text] [Related]
5. Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.
Villoutreix BO; Lilja H; Pettersson K; Lövgren T; Teleman O
Protein Sci; 1996 May; 5(5):836-51. PubMed ID: 8732755
[TBL] [Abstract][Full Text] [Related]
6. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution.
Sillerud LO; Burks EJ; Brown WM; Brown DC; Larson RS
J Pept Res; 2004 Oct; 64(4):127-40. PubMed ID: 15357668
[TBL] [Abstract][Full Text] [Related]
7. Structure-guided design of peptidic ligand for human prostate specific antigen.
Hassan MI; Kumar V; Somvanshi RK; Dey S; Singh TP; Yadav S
J Pept Sci; 2007 Dec; 13(12):849-55. PubMed ID: 17890654
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody.
Ménez R; Michel S; Muller BH; Bossus M; Ducancel F; Jolivet-Reynaud C; Stura EA
J Mol Biol; 2008 Feb; 376(4):1021-33. PubMed ID: 18187150
[TBL] [Abstract][Full Text] [Related]
9. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
10. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.
Mallik B; Katragadda M; Spruce LA; Carafides C; Tsokos CG; Morikis D; Lambris JD
J Med Chem; 2005 Jan; 48(1):274-86. PubMed ID: 15634022
[TBL] [Abstract][Full Text] [Related]
11. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
12. Cyclic peptide analysis of the biologically active loop region in the laminin alpha3 chain LG4 module demonstrates the importance of peptide conformation on biological activity.
Kato-Takagaki K; Suzuki N; Yokoyama F; Takaki S; Umezawa K; Higo J; Mochizuki M; Kikkawa Y; Oishi S; Utani A; Nomizu M
Biochemistry; 2007 Feb; 46(7):1952-60. PubMed ID: 17261031
[TBL] [Abstract][Full Text] [Related]
13. Backbone modifications in somatostatin analogues: relation between conformation and activity.
Van Binst G; Tourwé D
Pept Res; 1992; 5(1):8-13. PubMed ID: 1352471
[TBL] [Abstract][Full Text] [Related]
14. Why structurally different cyclic peptides can be glycomimetics of the HNK-1 carbohydrate antigen.
Bhunia A; Vivekanandan S; Eckert T; Burg-Roderfeld M; Wechselberger R; Romanuka J; Bächle D; Kornilov AV; von der Lieth CW; Jiménez-Barbero J; Nifantiev NE; Schachner M; Sewald N; Lütteke T; Hans-Joachim G; Siebert HC
J Am Chem Soc; 2010 Jan; 132(1):96-105. PubMed ID: 19958024
[TBL] [Abstract][Full Text] [Related]
15. High-affinity peptide ligands to prostate-specific antigen identified by polysome selection.
Gersuk GM; Corey MJ; Corey E; Stray JE; Kawasaki GH; Vessella RL
Biochem Biophys Res Commun; 1997 Mar; 232(2):578-82. PubMed ID: 9125226
[TBL] [Abstract][Full Text] [Related]
16. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
Preece NE; Nguyen M; Mahata M; Mahata SK; Mahapatra NR; Tsigelny I; O'Connor DT
Regul Pept; 2004 Apr; 118(1-2):75-87. PubMed ID: 14759560
[TBL] [Abstract][Full Text] [Related]
17. Cyclic peptides from the loop region of the laminin alpha 4 chain LG4 module show enhanced biological activity over linear peptides.
Yokoyama F; Suzuki N; Haruki M; Nishi N; Oishi S; Fujii N; Utani A; Kleinman HK; Nomizu M
Biochemistry; 2004 Oct; 43(42):13590-7. PubMed ID: 15491165
[TBL] [Abstract][Full Text] [Related]
18. Modeling of prostate specific antigen and human glandular kallikrein structures.
Vihinen M
Biochem Biophys Res Commun; 1994 Nov; 204(3):1251-6. PubMed ID: 7526861
[TBL] [Abstract][Full Text] [Related]
19. Complete substitutional analysis of a sunflower trypsin inhibitor with different serine proteases.
Hilpert K; Hansen G; Wessner H; Volkmer-Engert R; Höhne W
J Biochem; 2005 Oct; 138(4):383-90. PubMed ID: 16272132
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
